How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
Youll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and…
276,470$
1,49%
Echtzeit-Aktienkurs Abbvie Inc.
Bid:
Ask:
Nachrichten zur Abbvie Inc. Aktie
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
Youll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and…
AbbVies Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
ABBVs Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.…
AbbVies Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
ABBVs epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III studys PFS…
Can ABBVs New Parkinsons Pill Strengthen Its Neuroscience Franchise?
AbbVies FDA approval of Juvmo expands its Parkinsons portfolio, with a commercial launch targeted for October 2026.…
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly…
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
AbbVies stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive…
AbbVie Wins FDA Nod for New Parkinsons Disease Drug Juvmo
ABBV wins FDA approval for Juvmo, expanding its Parkinsons portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.…
AbbVie: Nach Humira zurück auf Wachstumskurs – neue Milliardenpotenziale und KGV 16,4
AbbVie ist ein führender Biopharma-Konzern und ersetzt den Humira-Rückgang zunehmend mit neuen Wachstumstreibern aus Immunologie, Neurologie und Onkologie. Skyrizi…
The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
GOOGL, MA and ABBV headline todays research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks.…
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie bets on pipeline diversification amid patent cliffs, while J&Js higher profitability masks litigation risks, a choice between growth ambition…
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and…
Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut
ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran…
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly…
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.…
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
These companies are committed to rewarding shareholders.…
AbbVie’s Rinvoq wins EU approval for pediatric arthritis
AbbVie’s Rinvoq wins EU approval for pediatric arthritis…
AbbVies Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?
AbbVies market-beating days dont seem to be over yet.…
Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside
Citadel, Ken Griffins hedge fund, materially increased its stake in AbbVie; heres why you may want to follow that lead.…
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.…
AbbVies Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
ABBVs atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.…
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVies diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.…
AbbVies Immunology Franchise: From Skyrizi & Rinvoq to Whats Next
ABBVs Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.…
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie
…
ROUNDUP: Botox und Co. - Minimalinvasive Eingriffe immer gefragter
BERLIN (dpa-AFX) - Immer mehr Menschen lassen minimalinvasive Eingriffe beim Schönheitschirurgen durchführen. Zu minimalinvasiven Eingriffen gehören…